Related circRNAs in SMMC-7721 cells in the combined treatment of berberine and regorafenib

Resistance of regorafenib remains key issues for advanced Hepatocellular carcinoma (HCC) treatment. Berberine (BBR) has a beneficial role in enhancing chemotherapeutic effect when used in combination with other agents. Our data showed, for the first time, that BBR could enhanced the anti-HCC effect of regorafenib in vitro and in vivo. However, the mechanism is still unclear. The aim of this study was to explore the circRNA expression profile in SMMC-7721 cells in the combined treatment of berberine and regorafenib. We performed circular RNA profiling by high throughput sequencing to compare the expression of circRNAs in SMMC-7721 cells in berberine and regorafenib combined treatement group and the control group.